tiprankstipranks
AdaptHealth sees FY22 revenue near midpoint of prior guidance of $2.95B-$3.01B
The Fly

AdaptHealth sees FY22 revenue near midpoint of prior guidance of $2.95B-$3.01B

Consensus $2.98B. Sees FY22 adjusted EBITDA to be near the low end of the previously-provided guidance range of $620M-$650M. CEO Steve Griggs commented, "We are pleased with our guidance for the full year ending December 31, 2023 which reflects continued improvement and stabilization of the supply of PAP devices for our sleep business and overall non-acquired net revenue growth for the Company in the range of 8% to 10%. Demand remains very strong across our businesses and we are pleased with our ability to execute on that demand, addressing the needs of our patients and adding value for our partners. We continue to work on innovative technology solutions that allow us to seamlessly communicate with patients, providers and payers to take advantage of value-based care and chronic care management opportunities. At the same time, we are not immune to the cost of goods inflation and labor pressures that all operators in the healthcare industry are experiencing and we will continue to look for ways to drive efficiency and generate operating leverage."

Published first on TheFly

See the top stocks recommended by analysts >>

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles